Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
3.560
-0.100 (-2.73%)
At close: Dec 26, 2025, 4:00 PM EST
3.570
+0.010 (0.28%)
After-hours: Dec 26, 2025, 6:01 PM EST
Quince Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,582,750
Market Cap
198.23M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36 | 4 | 12.50% |
| Dec 31, 2023 | 32 | 11 | 52.38% |
| Dec 31, 2022 | 21 | -34 | -61.82% |
| Dec 31, 2021 | 55 | 17 | 44.74% |
| Dec 31, 2020 | 38 | 15 | 65.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
QNCX News
- 11 days ago - Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Business Wire
- 16 days ago - Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - Business Wire
- 4 weeks ago - Quince Therapeutics to Participate at Investor Events in December 2025 - Business Wire
- 6 weeks ago - Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results - Business Wire
- 6 weeks ago - Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Business Wire
- 2 months ago - Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting - Business Wire
- 3 months ago - Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript - Seeking Alpha
- 3 months ago - Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study - Business Wire